Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 4/20 | 0.42 |
| ▸ | RAMP3 | O60896 | 11/20 | 0.42 |
| ▸ | CALCR | P30988 | 11/20 | 0.42 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30547998 | 0.89 | CAPN1 (0.48) | CAPN1RAMP3CALCRCALCRLKEAP1 | |
| SCHEMBL30883252 | 0.85 | CAPN1 (0.46) | CAPN1RAMP3CALCRCALCRL | |
| SCHEMBL31281377 | 0.83 | CALCRL (0.51) | CAPN1CALCRLSLC6A2 | |
| SCHEMBL29379569 | 0.82 | CAPN1 (0.62) | CAPN1RAMP3CALCRCTSB | |
| SCHEMBL8625474 | 0.82 | CAPN1 (0.53) | CAPN1RAMP3CALCRCALCRLCTSB | |
| SCHEMBL29827592 | 0.80 | RAMP3 (0.53) | RAMP3CALCRKEAP1PTPN1 | |
| SCHEMBL29630325 | 0.80 | XIAP (0.50) | CAPN1CALCRLCTSBSLC6A2 | |
| SCHEMBL31307251 | 0.80 | CALCRL (0.47) | RAMP3CALCRCALCRL | |
| SCHEMBL31182552 | 0.80 | BACE1 (0.47) | CAPN1RAMP3CALCRCALCRLCTSB | |
| SCHEMBL29531335 | 0.80 | NTSR2 (0.47) | CAPN1CTSBSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | CAPN1 1736/4885RAMP3 3402/4885CALCR 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.